Sébastien Wieckowski1, Teresa Hemmerle2, Spasenja Savic Prince3, Béatrice Dolder Schlienger1, Sven Hillinger4, Dario Neri2, Alfred Zippelius5. 1. Cancer Immunology and Biology, Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland. 2. Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang-Pauli-Strasse 10, CH-8093 Zürich, Switzerland; Philochem AG, Libernstrasse 3, CH-8093 Otelfingen, Switzerland. 3. Institute of Pathology, University Hospital Basel, Schönebeinstrasse 40, CH-4003 Basel, Switzerland. 4. Department of Thoracic Surgery, University Hospital Zürich, Schmelzbergstrasse 12, CH-8091 Zürich, Switzerland. 5. Cancer Immunology and Biology, Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland; Medical Oncology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. Electronic address: Alfred.Zippelius@usb.ch.
Abstract
OBJECTIVES: Antibody-cytokine fusion proteins (immunocytokines) represent a novel class of armed antibodies in oncology. In particular, IL2- and TNF-based immunocytokines targeting the EDB domain of fibronectin and the A1 domain of tenascin-C have demonstrated promising anti-tumor activity and are currently investigated in Phase I and Phase II clinical trials. To advance the development of immunocytokines for NSCLC, we here report on the therapeutic efficacy of F8-IL2, an immunocytokine directed against the alternatively spliced EDA domain of fibronectin in a fully immunocompetent, orthotopic model of NSCLC, and the characterization of the target antigen expression in human NSCLC specimens. MATERIALS AND METHODS: We evaluated the therapeutic efficacy of the F8-IL2 immunocytokine utilizing a K-ras mutant, p53 deficient metastatic mouse model of NSCLC derived from the latest generation of genetically engineered and conditional tumor models. In parallel, we assessed the presence of the EDA domain of fibronectin by immunofluorescence in lung biopsies obtained from patients with NSCLC. RESULTS: The EDA domain of fibronectin was broadly expressed in lung metastases obtained from our model. Treatment with F8-IL2 induced substantial local changes within immune effector cell populations and demonstrated promising therapeutic efficacy as monotherapy. The target of F8-IL2, the EDA domain of fibronectin, was present in all human lung adenocarcinoma specimens tested. CONCLUSION: Both the therapeutic efficacy in a metastatic mouse model of NSCLC and the extensive presence of the EDA domain of fibronectin in human NSCLC biopsies support the rational development of therapies based on the F8-IL2 immunocytokine for the treatment of NSCLC.
OBJECTIVES: Antibody-cytokine fusion proteins (immunocytokines) represent a novel class of armed antibodies in oncology. In particular, IL2- and TNF-based immunocytokines targeting the EDB domain of fibronectin and the A1 domain of tenascin-C have demonstrated promising anti-tumor activity and are currently investigated in Phase I and Phase II clinical trials. To advance the development of immunocytokines for NSCLC, we here report on the therapeutic efficacy of F8-IL2, an immunocytokine directed against the alternatively spliced EDA domain of fibronectin in a fully immunocompetent, orthotopic model of NSCLC, and the characterization of the target antigen expression in humanNSCLC specimens. MATERIALS AND METHODS: We evaluated the therapeutic efficacy of the F8-IL2 immunocytokine utilizing a K-ras mutant, p53 deficient metastatic mouse model of NSCLC derived from the latest generation of genetically engineered and conditional tumor models. In parallel, we assessed the presence of the EDA domain of fibronectin by immunofluorescence in lung biopsies obtained from patients with NSCLC. RESULTS: The EDA domain of fibronectin was broadly expressed in lung metastases obtained from our model. Treatment with F8-IL2 induced substantial local changes within immune effector cell populations and demonstrated promising therapeutic efficacy as monotherapy. The target of F8-IL2, the EDA domain of fibronectin, was present in all humanlung adenocarcinoma specimens tested. CONCLUSION: Both the therapeutic efficacy in a metastatic mouse model of NSCLC and the extensive presence of the EDA domain of fibronectin in humanNSCLC biopsies support the rational development of therapies based on the F8-IL2 immunocytokine for the treatment of NSCLC.
Authors: Rodolfo Garza-Morales; Kavitha Yaddanapudi; Rigoberto Perez-Hernandez; Eric Riedinger; Kelly M McMasters; Haval Shirwan; Esma Yolcu; Roberto Montes de Oca-Luna; Jorge G Gomez-Gutierrez Journal: Cancer Biol Ther Date: 2018-01-22 Impact factor: 4.742
Authors: Franziska Eckert; Ivan Jelas; Moritz Oehme; Stephan M Huber; Katja Sonntag; Christian Welker; Stephen D Gillies; Wolfgang Strittmatter; Daniel Zips; Rupert Handgretinger; Karin Schilbach Journal: Oncoimmunology Date: 2017-04-28 Impact factor: 8.110
Authors: Maxime Dhainaut; Samuel A Rose; Guray Akturk; Aleksandra Wroblewska; Sebastian R Nielsen; Eun Sook Park; Mark Buckup; Vladimir Roudko; Luisanna Pia; Robert Sweeney; Jessica Le Berichel; C Matthias Wilk; Anela Bektesevic; Brian H Lee; Nina Bhardwaj; Adeeb H Rahman; Alessia Baccarini; Sacha Gnjatic; Dana Pe'er; Miriam Merad; Brian D Brown Journal: Cell Date: 2022-03-14 Impact factor: 66.850
Authors: Maciej Kujawski; Mark Sherman; Susanta Hui; Darren Zuro; Wen-Hui Lee; Paul Yazaki; Anakim Sherman; Barbara Szpikowska; Junie Chea; Desiree Lasiewski; Kofi Poku; Harry Li; David Colcher; Jeffrey Wong; John E Shively Journal: Oncoimmunology Date: 2020-02-14 Impact factor: 8.110